AU2008202374B2 - Genetically modified ecarin and process for producing the same - Google Patents

Description

AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant(s): JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE Invention Title: GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME The following statement is a full description of this invention, including the best method for performing it known to me/us: PS1790.AU I PatSeI_Fding Application 2008.5-28doc (M) DESCRIPTION GENETIC RECOMBINANT ECARIN AND PROCESS FOR PREPARING THE SAME 5 TECHNICAL FIELD The present invention relates to a novel polypeptide. More specifically, the present invention relates to a genetic recombinant ecarin that specifically activates prothrombin and a process for preparing said 10 genetic recombinant ecarin. BACKGROUND ART Some animals have a potent venom such as a snake venom, a spider venom, a scorpion venom, and a bee venom. It has been revealed that the venom comprises practically 15 useful substance including a neurotoxin, a bleeding toxin, a thrombotic toxin, a physiologically active peptide, a cell growth factor activity, and the like. Ecarin is a snake venom-derived protease isolated from Echis carinat-us (T. Morita et al.: J. Biochem. 83, 20 559-570, 1978), known to specifically activate prothrombin. A cDNA encoding ecarin has been cloned by S. Nishida et al. (Biochemistry, 34, 1771-1778, 1995) to reveal its structure. Ecarin, a sugar protein, is a metalloprotease, a mature form of which has 426 amino acid residues in total, having 25 a mosaic structure comprising a Zn" chelate, a disintegrin 2 domain and a Cys-rich domain, with 61% homology to an H chain of RVV-X (Russell's viper venom X activator). Ecarin is quite a distinct enzyme from Factor Xa since its enzymatic activity is inactivated by EDTA but is not 5 inhibited by DFP or antithrombin III. Prothrombin, a target substrate to be activated by ecarin, is a precursor of thrombin, one of various blood coagulation factors. Thrombin, produced as a consequence of activation, is a multifunctional serine protease capable 10 of interacting with various substrates and acting in a coagulation-anticoagulation manner within the living body. In human blood, prothrombin is activated by Factor Xa through restricted cleavage at two sites of prothrombin, i.e. Arg-Thr and Arg-Ile, whereas ecarin hydrolyzes 15 prothrombin at the Arg-Ile alone to produce meizothrombin having a comparatively large molecular weight. Conversion of prethrombin-2 (product after removal of gla domain and Kringle domain from prothrombin) into active thrombin (c thrombin) through Arg-Ile cleavage can surely be performed 20 by ecarin based on its high substrate specificity. Although the Arg-Ile cleavage can also be done by trypsin, belonging to the same serine protease as ecarin, trypsin apt to cleave additional sites other than said cleavage site whereas ecarin never cleaves any other sites than said 25 cleave site due to its high specificity as to the cleavage 3 site. When trypsin is used to activate prethrombin-2, although partial activation of prethrombin-2 into a thrombin is observed, most of the resulting a-thrombin is further degraded and hence complete conversion from 5 prethrombin-2 into a-thrombin is not possible. On the contrary, when ecarin is added to prethrombin-2, conversion of prethrombin-2 into a-thrombin can quantitatively be done without any side products since ecarin only cleaves the unique Arg-Ile in prothrombin-2. 10 In the living process where prothrombin is converted into a-thrombin, prothrombin is activated via the intermediate called meizothrombin as described above. Within the living body, prothrombin is cleaved first at its Arg-Ile site by Factor Xa to produce meizothrombin, which 15 is then cleaved by Factor Xa at the Arg-Thr site to complete activation to a-thrombin. Meizothrombin is known, though having a protease activity, to have a distinct substrate specificity from a-thrombin, as possessing an extremely low coagulating activity to fibrinogen while 20 retaining an ability to activate protein C. Exhibiting such a characteristic substrate specificity, meizothrombin is readily converted into a-thrombin and hence does not stably exist within the living body since Factor Xa cleaves the two sites in prothrombin, i.e. Arg-Thr and Arg-Ile, as 25 described above. Using ecarin for activation of 4 prothrombin, however, meizothrombin can stably be prepared as ecarin cleaves the Arg-Ile site alone. Moreover, since ecarin also acts on abnormal prothrombin produced biosynthetically in the absence of Vitamin K, it is utilized for measuring 5 blood level of such abnormal prothrombin. SUMMARY OF THE INVENTION A first aspect provides a process for preparing a genetic recombinant ecarin which comprises: 10 (1) culturing a transformant microorganismlor animal cell transformed with an expression vector in which a gene encoding proecarin is incorporated to the downstream of a promoter so as to produce and accumulate proecarin in culture supernatant or within said transformant and 15 recovering the produced genetic recombinant proecarin; (2) subjecting the genetic recombinant proecarin obtained in (1) to cation exchange chromatography at pH 5.0 to thereby activate the genetic recombinant proecarin to a genetic recombinant ecarin; 20 (3) subjecting the genetic recombinant ecarin obtained in (2) to cation exchange chromatography at pH 9.0 to thereby purify the genetic recombinant ecarin; and (4) subjecting the purified genetic recombinant ecarin obtained in (3) to gel filtration chromatography to thereby 25 remove impurities from a solution containing the genetic recombinant ecarin. 25255582_1 (GHMatters) 5 A second aspect provides a method of preparing meizothrombin from prothrombin comprising exposing prothrombin to the genetic recombinant ecarin obtained by the process of the first aspect. 5 A third aspect provides a method of activating prethrombin-2 into a-thrombin comprising exposing prethrombin-2 to the genetic recombinant ecarin obtained by the process of the first aspect. A fourth aspect provides a method of detecting abnormal 10 prothrombin comprising exposing a sample of prothrombin to the genetic recombinant ecarin obtained by the process of the first aspect. A fifth aspect provides use of the genetic recombinant ecarin obtained by the process of the first aspect to prepare 15 meizothrombin from prothrombin, to activate prethrombin-2 into a-thrombin, or to detect abnormal prothrombin. A sixth aspect provides use of the genetic recombinant ecarin obtained by the process of the first aspect in the preparation of a polyclonal or monoclonal antibody to ecarin. 20 A seventh aspect provides use of the genetic recombinant ecarin obtained by the process of the first aspect in the manufacture of a diagnostic agent. 25 252582_ 1 (GHMatters) 6 BRIEF DESCRIPTION OF DRAWINGS Fig. 1 illustrates expression plasmid pCAGG Sl(Sal).dhhr.neo. Fig. 2 shows the results of SDS-PAGE and protein 5 staining for fractions obtained in gel filtration, the final step in ecarin purification from culture supernatant of ecarin-producing SP2/0. Fig. 3 shows an activity to cleave 3-2238 after addition of a recombinant ecarin to prothrombin. 10 DETAILED DESCRIPTION As explained above, ecarin was found to possess an industrially useful activity. Up till the present, however, the only source is Echis carinatus and thus ecarin 15 has not yet been industrially utilized due to its limited quantitative availability. Under the present circumstances, ecarin is sold as a reagent by reagent manufacturers but, due to high price as well as insufficient provision, it is not possible to use ecarin for activating prethrombin-2 or for 20 preparing meizothrombin on an industrially applicable large scale. Besides, there is no guarantee that wild Echis carinatus is stably provided as a source and safety of working staffs must also be taken care of in view of the snake venom who handle a breeding of the snake. Putting all 25 these accounts together, one may readily find that obtaining a large amount of ecarin is much difficult. Taking into 2525882_1 (GHMattm) 7 consideration a risk and limitation in preparing ecarin from Echis carinatus, another source and method allowing for provision of ecarin in a safer and more stable manner is desired. 5 Thus, the present disclosure provides a genetic recombinant ecarin (hereinafter also referred to as "recombinant ecarin") capable of serving conversion from prethrombin-2 into a-thrombin or from prothrombin into meizothrombin via cleavage at the Arg-Ile site. This is 10 attained by providing a protein with a molecular weight of about 66,000 having an amino acid sequence as set forth in SEQ ID NO: 1, or a peptide fragment or a series of peptide fragments having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or 15 added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. Also provided by the present disclosure are a gene fragment that encodes a recombinant proecarin and has a 20 nucleotide sequence as set forth in SEQ ID NO: 2, or gene fragments that encode peptides having a partial amino acid sequence of said protein, as well as a plasmid comprising these gene fragments. The present disclosure also encompasses a recombinant microorganism and animal cell transformed with 25 said plasmid. The present disclosure further encompasses a method for preparing a recombinant ecarin of interest or 252582_I (GHMatter) 8 peptides having a partial amino acid sequence of the recombinant ecarin using these transformed microorganism or animal cells. A gene encoding proecarin protein can be obtained by 5 PCR using the sequence reported in the literature (S. Nishida et al., Biochemistry, 34, p.17 7 1-1 77 8, 1995) as a template and synthetic DNAs as set forth in SEQ ID NO: 3 and SEQ ID NO: 4 as a primer pair. Proecarin or a partial protein thereof canbe prepared 10 by incorporating a cDNA fragment encoding a porLion of a structural region of a full length proecarin protein into an expression vector, transforming suitable microorganism or animal cells with the resulting expression vectpr, and culturing the transformant microorganism or animal cells to 15 produce proecarin or a partial protein thereof.- For production of a partial protein of proecarin, a peptide synthesizer may also be used. An appropriate signal sequence for secretion in microorganism or animal cells may be linked to-the upstream 20 of a DNA encoding the protein so that said protein may be expressed and secreted into a culture medium. The thus modified DNA for the purpose of secretion is advantageous in that the protein secreted into a culture medium can readily be recovered. Such a signal sequence includes pel B signal 25 (S. P Lei et al., J. Bacteriology Vol. 169, 4379-4383, 1987) for E. coli; a factor signal (A. J. Brake, Yeast Genetic 2525682_1 (GHMatt..) 9 Engineering, p269 Butterworth, 1989) for yeast; immunoglobulin signal SG-1 (H. Maeda et al., Hum. Antibod. Hybridomas Vol. 2, 124-134, 1991), C25 signal (Patent, International Publication No. W094/20632) for animal cells, 5 and the like. An expression vector that can be used includes a plasmid, a viral vector, and the like. A promoter to be contained in the expression vector may be any promoter as far as it can ultimately provide active ecarin protein when 10 combined with microorganism or animal cells as a host cell, including SV40 early promoter, SV40 late promoter, Cytomegalovirus promoter, chicken a-actin promoter, and the like. A marker gene includes, in case of an expression vector for a microorganism, an ampicilin resistance gene, 15 tetracycline resistance gene for E. coli as a host; Leu2 gene for yeast as a host, and the like. In case of an expression vector for an animal cell, aminoglycoside 3'phosphotransferase (neo) gene, dihydrofolate reductase (dhfr) gene, glutamine synthetase (GS) gene, and the like, 20 may be used. Fig. 1 shows pCAGG-Sl(Sal) .dhhr.neo as a exemplary expression vector wherein substance to be added for selection includes G418, neomycin, methotrexate, and the like. In case of an expression vector for an animal 25 cell, a variety of cells such as Chinese hamster ovary 2525e82_1 (GHMatters) 10 (CHO) cell, mouse myeloma cell, e.g. SP2/0, BHK21 cell, 293 cell and COS cell may be used as a host cell. With the thus constructed proecarin expressing cells, proecarin may be expressed transiently using e.g. COS7 cell (derived from 5 African green monkey) or expressed stably using'SP2/0 cell or CHO cell as a host cell. A host cell may be transformed by any known methods including, for example, a calcium phosphate method, a DEAE dextran method, precipitation with e.g. lipofectin, 10 fusion of protoplast with polyethylene glycol, electroporation, and the like. A method for transformation may suitably be selected depending on a host cell as used. The recombinant ecarin may be prepared as described below. The animal cells that stably express proecarin are 15 cultured under normal conditions, for example, in MEN alpha culture medium containing 400 pg/mL to 1 mg/mL neomycin and 10% FCS in case that neomycin resistance gene is used as a marker gene to prepare neomycin resistant cells and then the enzymatic activity of ecarin in culture supernatant is 20 measured. A clone that can grow under serum free conditions is then obtained from the proecarin producing transformants and cultured in a large scale. Ecarin is prepared and purified from the culture supernatant recovered therefrom with an index of the activity of ecarin to convert 25 prothrombin into a-thrombin. 2525082.1 (GHMattem) 10a The recombinant proecarin may be isolated and purified by any method conventionally used in the field of protein chemistry, as appropriately selected, including e.g. a salting out, ultrafiltration, isoelectric focusing, 5 electrophoresis, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, affinity chromatography, etc., with an index of the ability to activate prothrombin as described above. In one embodiment the recombinant proecarin is subjected to 10 cation exchange chromatography and gel filtration chromatography in this order under conditions as described in Example 9. This allows for activation and purification of the recombinant proecarin protein to produce ecarin'protein having around 2,600-fold higher specific activity with an 15 activity yield of 13% with an index of the ability to activate prothrombin. The fraction thus obtained after purification is then subject to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis in the presence of 2 20 mercaptoethanol to detect a main band of around 66,000 M.W. (Fig. 2) The thus obtained ecarin has an activity to activate prothrombin. The ecarin protein may be utilized for preparing meizothrombin from prothrombin, for activating prethrombin-2 25 into a-thrombin, or for use as a detection reagent for abnormal prothrombin. 2525082_1 (GHMattrs.) I Ob Besides, the ecarin protein or a polypeptide having a partial amino acid sequence thereof may also be utilized as an immunogen for preparing a polyclonal or monodlonal antibody by a conventional method. The thus 5 2525082_1 (GHMatter) 11 prepared antibody capable of binding to the ecarin protein or a polypeptide having a partial amino acid sequence thereof as well as said protein or the polypeptide may be used in a detection system for an antigen such as Western 5 blot or ELISA and as a material for constructing a diagnostic agent. Alternatively, the antibody may be bound to a suitable carrier for use in affinity chromatography to purify the antigenic proteins. The present invention is explained in more detail 10 by means of the following Examples which are not intended to restrict a scope of the present invention in any sense. Reagents used in the following Preparation and Examples were obtained from Pharmacia, BioRad, Wako Pure Chemical Industries, Ltd., TAKARA SHUZO CO., Ltd., Toyobo, and New 15 England BioLabs. Example 1 (Construction of expression plasmid) (1) Construction of expression plasmid pCAGG-Sl (Sal) A chicken @-actin promoter-based expression 20 plasmid pCAGG (Japanese Patent Publication No. 168087/1991) was digested with restriction enzyme EcoRI, blunt ended with T4 DNA polymerase, and then ligated with T4 DNA ligase in the presence of phosphorylated XhoI linker to construct pCAGG(Xho). The obtained pCAGG(Xho) was digested with 25 restriction enzyme SalI, blunt ended with T4 DNA polymerase, 12 and then ligated with T4 DNA ligase to construct pCAGG-Pv2. The resulting pCAGG-Pv2 was digested with restriction enzyme XhoI and then treated with Si nuclease to erase several nucleotides in the vicinity of the XhoI recognition 5 site. After the nuclease treatment, a single chain region was modified with T4 DNA polymerase in the presence of dNTPs and then ligated with T4 DNA ligase in the presence of phosphorylated SalI linker to construct pCAGG-Sl (Sal). (2) Construction of expression plasmid pCAGG-Sl (Sal) .dhfr 10 Expression plasmid pSV2-dhfr bearing DHFR gene (S. Subramani et al., Mol. Cell. Biol., 1, p.854-864, 1981) was digested with restriction enzyme BglII, blunt ended with T4 DNA polymerase, and ligated with T4 DNA ligase to construct pSV2-dhfr-Bgn. The resulting pSV2-dhfr-Bgn was then 15 digested with restriction enzyme PvuII and ligated with T4 DNA ligase in the presence of phosphorylated BglII linker to construct pSV2-dhfr-BgB. The obtained pSV2-dhfr-BgB was digested with restriction enzymes BglII and BamHI and was then subject to agarose gel electrophoresis to obtain a 20 fragment of about 1.7 kbp. The expression plasmid pCAGG Sl(Sal) obtained above was digested with restriction enzyme BamHI and then ligated to cyclize with the 1.7 kbp fragment to construct pCAGGS1(Sal).dhfr. (3) Construction of expression plasmid pCAGG 25 Sl(Sal).dhfr.neo 13 An aminoglycoside phosphotransferase (neo')-based expression plasmid pMClneo-polyA (K. R. Thomas et al., Cell, 51, p.503-512, 1987) was digested with restriction enzyme XhoI and then ligated with T4 DNA ligase in the presence of 5 phosphorylated BamHI linker to construct pMClneo-2B. The resulting pMClneo-2B was digested with restriction enzyme BamHI and then subject to agarose gel electrophoresis to obtain a fragment of about 1.1 kbp. The expression plasmid pCAGG-Sl (Sal) .dhfr obtained above was digested with 10 restriction enzyme BamHI and then ligated to cyclize with the fragment of about 1.1 kbp to construct pCAGG Sl(Sal).dhfr.neo (Fig. 1). Example 2 (Preparation of cDNA of snake venom ecarin) 25 Using the nucleotide sequence of ecarin cDNA reported in the literature (S. Nishida et al., Biochemistry, 34, p.1771-1778, 1995) as a template, PCR was conducted using a synthetic DNA having the sequence: ATGCACTCGAGATGATCCAGATTCTCTTGGT (SEQ ID NO: 3) 20 and a synthetic DNA having the sequence: TGCATCTCGAGTTAGTAGGCTGTATTCACA (SEQ ID NO: 4) as a primer pair to introduce the recognition sites of restriction enzyme XhoI at both termini. The obtained gene was digested with restriction enzyme XhoI and subcloned 25 into pUC18 to construct pUC.EC. A nucleotide sequence of 14 the proecarin cDNA region of the resulting plasmid was determined by the conventional method to thereby obtain proecarin cDNA that has an exactly identical nucleotide sequence from the initiation codon to the termination codon 5 to the sequence reported in the literature (SEQ'ID NO: 2). The proecarin cDNA obtained herein encodes the polypeptide as set forth in SEQ ID NO: 1. Example 3 (Construction of proecarin expression plasmid) 10 The proecarin cDNA obtained in Example 2 was incorporated into the expression vector pCAGG S1(Sal).dhfr.neo obtained in Example 1. The plaamid pCAGG Sl(Sal).dhfr.neo was digested with restriction enzyme SalI and then dephosphorylated with bovine small intestine 15 derived alkaline phosphatase. The plasmid pUC.EC obtained above was digested with restriction enzyme XhoI and then a fragment of about 1.8 kbp encoding proecarin cDNA was purified by agarose gel electrophoresis. Then, the dephosphorylated plasmid and the fragment encoding proecarin 20 cDNA were ligated to cyclize with T4 DNA ligase to construct pCAGG-Sl.EC.dhfr.neo. Example 4 (Expression of proecarin using animal cells) The proecarin expression plasmid pCAGG 25 Sl.EC.dhfr.neo described in Example 3 was used to transform CHO cells and SP2/0 Agl4 cells. CHO cells were transformed by 2525682_1 (GHMatter) 15 a modified calcium phosphate method whereas SP2/0-Ag14 cells were transformed by electroporation. The expression plasmid for use in transformation was previously linearized by digestion with restriction 5 enzyme PvuI. (1) Assessment of ability to produce proecarin with CHO cells Using CHO cells, transformants were selected from transformation as described below. On the day previous to transformation, the cells were 10 plated in MEM alpha medium with nucleic acids supplemented with 10% fetal calf serum in 10 cm dish at a cellular density of 5 x 105 cells/dish. After culture at 37 0 C overnight, the cells were transformed with 20 pg/mL of the linearized expression plasmid pCAGG-Sl.EC.dhfr.neo. After culture in 3% 15 CO 2 incubator at 35 0 C overnight, the cells werewashed with Dulbecco PBS(-) and the culture medium was replaced with nucleic acid free MEM alpha medium containing 10% dialyzed FCS and 500 pg/mL Geneticin. For selection, culture was continued in 5% CO 2 incubator at 37 0 C while replacing the 20 culture medium every 3 to 4 days and emerged transformants were pooled and assessed for their ability to produce ecarin. The transformed cells were plated in nucleic acid free MEM alpha medium supplemented with 10% dialyzed FCS at a density of 2 x 105 cells/mL and cultured overnight. The next 25 day, the culture medium was replaced with serum free YMM medium (nucleic acid free MEM alpha medium with enriched 2525682_1 (GHMattes) 16 amino acids/vitamins containing insulin, transferrin, ethanolamine and sodium selenite). After culture in 5% CO 2 incubator at 350C for about 14 days, a proecarin level in culture supernatant was measured. As a result, 10 U/ml of 5 proecarin in the culture supernatant was detected. (2) Assessment of ability to produce proecarin with SP2/0 cells Using SP2/0 cells, transformants were selected from transformation as described below. 10 SP2/0 cells were washed twice with cooled Dulbecco PBS (-) and 107 cells suspended in 0.8 ml of PBS(-) ,were placed in a cuvette for electroporation (electrode width 0.4 cm; manufactured by BIO-RAD). The linearized expression plasmid (40 pg) was added and mixed with pipette. One pulse was 15 applied at 0.22 kv at 975 pF using Gene Pulser II (manufactured by BIO-RAD). After the cuvette was cooled on ice for 10 minutes, the cell suspension was diluted with MEN alpha medium with nucleic acids containing 10% fetal calf serum (FCS) to about 5,000 cells/50 pL, plated on five 96 20 well plates each at 50 pL/well, and cultured in 3% CO 2 incubator at 35 0 C overnight. The next day, 50 pL/well of nucleic acid free MEN alpha medium containing 1.0% dialyzed FCS was added and culture was further continued overnight. The next day, 100 pL/well of nucleic acid free MEM alpha 25 medium containing 1 mg/Ml Geneticin and 10% dialyzed FCS was added. After culture for 10 to 14 days, emerged transformants 252582_1 (GHMatters) 17 at each well were assessed for their ability to produce proecarin. The cells were plated with nucleic acid free MEM alpha medium containing 500 pg/mL Geneticin and 2% dialyzed FCS at a density of about 3 x 105 cells/mL. After culture for 5 about 14 days, a proecarin level in culture supernatant was measured. As a result, each of the transformants was found to express 2 to 10 U/mL of proecarin. Among these transformants, each 200 pL/well of those producing a high level of proecarin were plated on 96-well plate at a concentration of 0.5 10 cell/well with the same culture medium for cloning by limiting dilution. Each of the obtained clones was assessed for their ability to produce proecarin. Each clone was plated with nucleic acid free MEM alpha medium containing 2% dialyzed FCS at a density of 3 x 105 cells/mL. After culture 15 in 5% Co 2 incubator at 35 0 C for about 14 days, a proecarin level in culture supernatant was measured. Among the obtained clones, clone #1H-8 expressed 15 U/mL proecarin' in culture supernatant. This clone #1H-8 was adapted to serum free medium 20 using YMM medium. YMM medium with 2% dialyzed FCS was used for culture and growth of the cells was confirmed. Thereafter, culture was continued while the serum level to be added was gradually lowered to 0.5% and further to 0.1%. After the cells were confirmed to proliferate well, they 25 were cultured with completely serum free YMM medium. Growth of the cells was confirmed and then their ability to produce 252582_ I (GHMatters) 18 proecarin was assessed by the method described above using YMM medium. The clone #1H-B after adaptation to serum free culture possessed an ability to produce 20 U/mL proecarin. Example 5 5 (Large scale culture of proecarin producing cells) The proecarin producing cells #1H-8, adapted to serum free culture as described in Example 4, were subject to suspension culture with a spinner flask. After expansion of the cells, 250 mL of the cells were cultured with YMM 10 medium in a 250 mL spinner flask (manufactured by Techne) at a density of 2 x 105 cells/mL. The cells were expanded to a 1 L spinner flask at a density of more than 1 x lb6 cells/mL. After growth of the cells was confirmed, the cells were further expanded to five 1 L spinner flasks. The cells were 15 cultured for about 7 days and then a proecarin -level in culture supernatant was measured to detect expression of about 18 U/mL proecarin. Example 6 (Preparation of antibody against partial peptide of ecarin) 20 An amino acid sequence encoded by the proecarin cDNA was analyzed for its hydrophilic and hydrophobic regions in accordance with Hopp and Wood (T. P. Hopp et al., Proc. Natl. Acad. Sci. Vol. 78, 3824-3828, 1981) . As a high hydrophilicity region, a peptide having the amino acid 25 sequence: Lys-Asn-Asp-Tyr-Ser-Tyr-Ala-Asp-Glu-Asn-Lys-Gly Ile-Val-Glu-Pro-Gly-Thr-Lys-Cys as set forth in SEQ ID NO: 2525082_1 (GMMattem) 19 5 was synthesized with a peptide synthesizer (manufactured by Applied). This peptide (500 pg) was inoculated to rabbit intradermally in the presence of Freund complete adjuvant on Day 0 and in the presence of Freund incomplete adjuvant on 5 Day 14 and Day 28 to prepare a polyclonal antibody against the ecarin peptide. Western blot was used to confirm whether the obtained antibody recognizes ecarin. Natural ecarin was subject to SDS-PAGE in the absence of 2-mercaptoethanol. After electrophoresis, the gel was immersed in a transfer 10 buffer (10 mM N-cyclohexyl-3-aminopropanesulfonic acid, 10% methanol, pH 11) for 5 minutes and then overlayed on PVDF membrane (Immovilon: Millipore) previously immersed in 100% methanol and the transfer buffer in this order to perform transfer at 160 mA for 16 hours using TRANS-BLOTCELL (BIO 15 RAD). After masking with TBST (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.05% Tween 2525682_ (GHMater) 20 20, containing 5% skim milk), the membrane was incubated with the serum diluted by 500-fold with TBST from rabbit to which the synthetic peptide was administered at room temperature for 1 hour and then washed with TBST. Then, 5 the membrane was reacted with anti-rabbit IgG-HRP labeled antibody (Bio-Rad) diluted by 2,000-fold at room temperature for 1 hour. After washing, the membrane was dyed with Konica Immunostaining HRP 1000 (Konica) kit. As a result, the serum obtained by immunization with the 10 synthetic peptide proved to specifically react with ecarin. ExampIe 7 (Purification of ecarin) (1) Cation exchange chromatography Culture supernatant (2000 mL) from the ecarin 15 producing SP2/0 cells was diluted with a twice amount of water, adjusted to pH 5.0 with 1M citric acid and filtered through 0.45 pm filter to be used as a sample. The sample was applied to Macro-Prep High S Support (20 mL: Bio-Rad Laboratories) column equilibrated with 20 mM citrate (pH 20 5.0) buffer at a flow rate of 4 mL/min. The column was washed with the same buffer (150 mL) and then eluted with a gradient of salt concentration ranging from 0 mM to 1000 mM NaCl/20 mM citric acid (pH 5.0; 210 mL) at a flow rate of 4 mL/min. A portion of fractions was used for Western blot 25 with the anti-ecarin antibody obtained in Example 6 to 21 identify fractions with eluted ecarin, which were pooled and dialyzed against 20 mM sodium hydrogen carbonate buffer (pH 9.0) containing 50 mM NaCl. (2) Cation exchange chromatography 5 The dialyzed product obtained in the process of cation exchange chromatography (1) above was applied to sulfate Cellulofine (2 mL: SEIKAGAKU CORPORATION) column equilibrated with 20 mM sodium hydrogen carbonate buffer (pH 9.0) containing 50 mM NaCl at a flow rate of 0.5 mL/min. 10 The column was washed with the buffer described above (14 mL) and then eluted with a gradient of salt concentration ranging from 50 mM to 600 mM NaCl/20 mM sodium hydrogen carbonate (pH 9.0; 20 mL) at a flow rate of 0.5 mL/min. A portion of fractions was used for Western blot with the 15 anti-ecarin antibody obtained in Example 6 to identify and pool fractions with eluted ecarin. (3) Gel filtration The fractions containing the recombinant ecarin obtained in the process of chromatography (2) above were 20 applied to gel filtration column HiLoad 16/60 (Pharmacia) equilibrated with 10 mM phosphate (pH 7.0) buffer containing 100 mM NaCl and fractionated at a flow rate of 0.5 mL/min. A marker for gel filtration (Bio Rad) was used as a molecular weight standard. Each of the fractions was 25 measured for an ability to activate prothrombin to detect a 22 peak activity in a fraction of about M.W. 66,000. The obtained fraction of purified ecarin was subject to SDS-PAGE in the presence of 2-mercaptoethanol with subsequent treatment with Coomassie Brilliant Blue. The obtained 5 pattern is shown in Fig. 2. The above three-step purification gave the recombinant ecarin with 13% of final activity yield and 2,600-fold higher specific activity as compared to culture supernatant. Example 8 10 (Activation of prothrombin by recombinant ecarin) To prothrombin (20 mM Tris-HCl, 100 mM NaCl, pH 8.5; 1 mg/mL; 40 mL) was added benzamidine to a final concentration of 50 mM. The recombinant ecarin was added to the mixture to a final concentration of 2 U/mL. The reaction mixture was 15 incubated at 370C for 16 hours and then determined for the enzymatic activity of thrombin in accordance with the method as described below. As a result, the activity to cleave S 2238 was detected in prothrombin when added with the recombinant ecarin as shown in Fig. 3. 20 Example 9 (N-terminal amino acid sequence of prothrombin B chain activated by recombinant ecarin) It is known that ecarin specifically cleaves the peptide bond in prothrombin at the Arg-Ile site to produce 25 252582_1 (GHMatters) 23 A chain and B chain from prothrombin. The N-terminal amino acid sequence of thrombin B chain obtained after activation in Example 8 was determined. The sample was run on SDS-PAGE gel containing 15% 5 polyacrylamide with 2-mercaptoethanol treatment. After electrophoresis, the gel was immersed in a transfer buffer (10 mM N-cyclohexyl-3-aminopropanesulfonic acid, 10% methanol, pH 11) for 5 minutes and then overlayed on PVDF membrane (Immovilon: Millipore) previously immersed in 100% 10 methanol and the transfer buffer in this order to perform transfer at 160 mA for 16 hours using TRANS-BLOTCELL (BIO RAD) . The PVDF membrane after transfer was washed with water, dyed with 0.1% Amide Black (containing 40% methanol, 1% citric acid) for 1 minute and then decolorized with 15 distilled water. A dyed band corresponding to the molecular weight of B chain was cut and the membrane fragment was analyzed with 477A Protein Sequencer (Applied Biosystems) . A sequence of ten amino acid residues at the N-terminus was determined: Ile-Val-Glu-Gly-Ser-Asp-Ala-Glu 20 Ile-Gly. This sequence is identical to the N-terminal amino acid sequence of B chain of x-thrombin derived from human blood, demonstrating that the recombinant ecarin obtained according to the present invention specifically cleaves the peptide bond at the Arg-Ile site in prothrombin 25 like snake venom derived ecarin.

24 Measurement of activity of thrombin and ecarin in Examples as described above was performed as follows: (1) Measurement of thrombin activity An activity of thrombin was measured as described 5 blow. A sample (20 iL), 50 mM Tris-HCl, pH 8.5 plus 50 mM NaCl buffer (60 pL), and 0.1% PLURONIC F-68 (20 pL) were added to 2008 tube (Falcon) and incubated at 37 0 C for 3 minutes. A purified c-thrombin derived from human plasma 10 (purchased from Hematologic Technology: HCT-0020) was used as a standard with dilution to 5, 2.5, 1.25, 0.625, and 0.3125 pg/mL using the same buffer. To the reaction mixture was added 100 1.L of TestTeam developing substrate S-2238 (1 mM: DAIICH PURE CHEMICALS CO., LTD.) while 15 stirring. After reaction at 37 0 C for 5 minutes, the reaction was quenched with 800 pL of 0.1 M citric acid. The reaction solution (200 pL) was transferred to a 96-well plate and OD 405/650 was measured. (2) Measurement of ecarin activity 20 An activity of ecarin was measured as described blow. A sample (20 pL), and 50 mM Tris-HCl, pH 8.5 plus 50 mM NaCl plus 0.1% PLURONIC F-68 buffer ("Buffer 1"; 60 pL) were added to 2008 tube (Falcon). Thereto was added 25 0.01% trypsin (2 pL) and the mixture was stirred and 25 incubated at 37 0 C for 10 minutes. The sample was diluted with Buffer 1 as needed depending on its concentration. To the reaction solution was added 10 pL of prothrombin (0.4 mg/mL; purchased from Hematologic Technology) and the 5 mixture was reacted at 37*C for 5 minutes. Then, 10 mM EDTA (10 pL) and TestTeam developing substrate S-2238 (1 mM; 100 pL) were added to the reaction mixture while stirring. After reaction at 37*C for 5 minutes, the reaction was quenched with 800 pL of 0.1 M citric acid. 10 The reaction solution (200 pL) was transferred to a 96-well plate and OD 405/650 was measured. For quantification of an ecarin activity, ecarin derived from snake venom (commercially available from Sigma) was diluted to 25 mU/mL, 12.5, 6.25, and 3.125 mU/mL with Buffer 1. Each 20 pL of 15 these standard solutions was used in place of the sample without addition of the trypsin solution and the steps described above following the addition of prothrombin were repeated. In accordance with the present invention, the 20 recombinant ecarin protein that specifically activates prothrombin is provided. The recombinant ecarin prepared by the present inventors as described herein is a novel protein not previously reported. Thus, technical problems for attaining practical usage of a recombinant ecarin 25 protein, such as construction of an expression vector that 26 expresses an active ecarin protein, preparation of cells stably expressing a recombinant ecarin, and purification of a recombinant ecarin, are solved by the present invention, thus allowing for preparation of said protein on industrial 5 scale. The entire disclosure in the complete specification of our Australian Patent Application No. 2002318574 is by this cross-reference incorporated into the present specification. It is to be understood that, if any prior art 10 publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. In the claims which follow and in the preceding 15 description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not 20 to preclude the presence or addition of further features in various embodiments of the invention. 2525682_1 (GHMatters)

Claims (18)

1. A process for preparing a genetic recombinant ecarin which comprises: (1) culturing a transformant microorganism or animal 5 cell transformed with an expression vector in which a gene encoding proecarin is incorporated to the downstream of a promoter so as to produce and accumulate proecarin in culture supernatant or within said transformant and recovering the produced genetic recombinant proecarin; 10 (2) subjecting the genetic recombinant proecarin obtained in (1) to cation exchange chromatography at pH 5.0 to thereby activate the genetic recombinant proecarin to a genetic recombinant ecarin; (3) subjecting the genetic recombinant ecarin obtained 15 in (2) to cation exchange chromatography at pH 9.0 to thereby purify the genetic recombinant ecarin; and (4) subjecting the purified genetic recombinant ecarin obtained in (3) to gel filtration chromatography to thereby remove impurities from a solution containing the genetic 20 recombinant ecarin.

2. The process for preparing a genetic recombinant ecarin of claim 1 wherein said promoter is selected from the group consisting of SV40 early promoter, SV40 late promoter, 25 Cytomegalovirus promoter and chicken P-actin promoter. 2525082_1 (GHMatters) 28

3. The process for preparing a genetic recombinant ecarin of claim 2 wherein said promoter is chicken P-actin promoter.

4. The process for preparing a genetic recombinant ecarin 5 of any one of claims 1 to 3 wherein said expression vector contains a signal sequence at the upstream of a'gene encoding proecarin.

5. The process for preparing a genetic recombinant ecarin 10 of claim 4 wherein said signal sequence is selected from the group consisting of pel B signal, a factor signal, immunoglobulin signal SG-1 and C25 signal.

6. The process for preparing a genetic recombinant ecarin 15 of any one of claims 1 to 5 wherein said expression vector further contains a gene amplification gene and the transformant is cultured under conditions suitable for gene amplification. 20

7. The process for preparing a genetic recombinant ecarin of claim 6 wherein said gene amplification gene is a gene encoding dihydrofolate reductase. 25256821 (GHMatters) 29

8. The process for preparing a genetic recombinant ecarin of any one of claims 1 to 7 wherein said gene encoding proecarin is a gene fragment having the nucleotide sequence as set forth in SEQ ID NO: 2 or a gene fragment 'encoding a 5 peptide comprising a partial amino acid sequence of said proecarin protein.

9. The process for preparing a genetic recombinant ecarin of any one of claims 1 to 8 wherein said transformant is an 10 animal cell selected from the group consisting of Chinese hamster ovary cell (CHO cell), mouse myeloma cell, BHK21 cell, 293 cell and COS cell.

10. The process for preparing a genetic recombLinant ecarin 15 of claim 1 wherein the purification process of 'carin consists of cation exchange chromatography and gel filtration chromatography being conducted in this order.

11. The process for preparing a genetic recombinant ecarin 20 of any one of claims 1 to 9, wherein said gene encoding proecarin is a gene fragment encoding the amino acid sequence as set forth in SEQ ID NO: 1.

12. A method of preparing meizothrombin from prothrombin 25 comprising exposing prothrombin to the genetic recombinant ecarin obtained by the process of any one of claims 1 to 11. 2525082_1 (GHMatters) 30

13. A method of activating prethrombin-2 into a-thrombin comprising exposing prethrombin-2 to the genetic recombinant ecarin obtained by the process of any one of claims 1 to 11. 5

14. A method of detecting abnormal prothrombin comprising exposing a sample of prothrombin to the genetic recombinant ecarin obtained by the process of any one of claims 1 to 11.

15. Use of the genetic recombinant ecarin obtained by the 10 process of any one of claims 1 to 11 to prepare'meizothrombin from prothrombin, to activate prethrombin-2 into a-thrombin, or to detect abnormal prothrombin.

16. Use of the genetic recombinant ecarin obtained by the 15 process of any one of claims 1 to 11 in the preparation of a polyclonal or monoclonal antibody to ecarin.

17. Use of the genetic recombinant ecarin obtained by the process of any one of claims 1 to 11 in the manufacture of a 20 diagnostic agent.

18. The process of claim 1, method of claim 12, 13 or 14, or use of claim 15, 16 or 17, substantially as hereinbefore described with reference to the accompanying examples and/or 25 figures. 2525682_l (GHMatms)